Bicycle Therapeutics PLC expected to post a loss of 84 cents a share - Earnings Preview

Bicycle Therapeutics

28/04/2025 13:36

Bicycle Therapeutics PLC BCYC.OQ BCYC.O is expected to show a fall in quarterly revenue when it reports  results on April 30 (estimated) for the period ending March 31 2025

The Cambridge Cambridgeshire-based  company is expected to report a 60.1% decrease in revenue to $7.784 million from $19.53 million a year ago, according to the mean estimate from 11 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Bicycle Therapeutics PLC is for a loss of 84 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Bicycle Therapeutics PLC is $30.00​, above​ its last closing price of $8.42. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.82
-0.86
-0.82
Beat
4.5
Sep. 30 2024
-0.75
-0.78
-0.74
Beat
5.3
Jun. 30 2024
-1.06
-1.10
-0.77
Beat
29.9​
Mar. 31 2024
-1.25
-1.24
-0.62
Beat
50.1
​​Dec. 31 2023
-1.17
-1.23
-1.16
Beat
6
Sep. 30 2023
-1.16
-1.17
-1.26
Missed
-7.6​
Jun. 30 2023
-1.31
-1.29
-1.41
Missed
-9
Mar. 31 2023
-1.08
-1.07
-1.30
Missed
-21.1

This summary was machine generated April 28 at 12:36 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)